*|MC_PREVIEW_TEXT|*


** Pharma Intelligence for Industry Leaders
------------------------------------------------------------


** Gracell's Clinical Trial, Ionis-Roche Partnership, VBI's Vaccine Progress
------------------------------------------------------------

Post-market Yesterday

Gracell Biotechnologies has dosed its first patient in a Phase 1b/2 clinical trial evaluating GC012F for treating relapsed/refractory multiple myeloma. This marks a significant milestone in their clinical development pipeline.

Galecto has announced plans to explore strategic alternatives. This could potentially result in significant changes to the company's future operations and strategic direction.

Rocket Pharmaceuticals will participate in the Chardan 7th Annual Genetic Medicines Conference. This participation demonstrates the company's ongoing commitment to engaging in industry dialogues.

MEI Pharma has reported its fiscal year 2023 results and operational highlights. The report details the company's performance and gives insight into its future plans.

Adverum Biotechnologies has announced positive Aflibercept protein level data from the LUNA Phase 2 trial. This positive data suggests progress in the company's clinical development.

Cardiff Oncology has announced positive clinical data in pancreatic cancer and small cell lung cancer. The data showcases the potential of Onvansertib monotherapy as an effective treatment option.

Pre-market Today

IDEAYA Biosciences has received fast track designation for IDE161. This designation could significantly expedite the development and review process for the drug.

Ionis has entered an agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease. This collaboration could potentially lead to breakthroughs in these two neurological diseases.

Precision BioSciences has received a U.S. patent allowance covering PBGENE-PMM for m.3243-associated mitochondrial diseases. This patent reinforces the company's intellectual property portfolio.

VBI Vaccines' pan-coronavirus vaccine candidate, VBI-2901, has induced broad and durable protective titers against variants of concern. This marks a significant step forward in the fight against COVID-19.

Viatris and Ocuphire Pharma have announced FDA approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the treatment of pharmacologically-induced Mydriasis. This approval expands the treatment options available to patients.

Nektar Therapeutics has announced a new clinical study collaboration with Cellular Biomedicine Group Inc. to evaluate NKTR-255 in combination with C-TIL051 in advanced non-small cell lung cancer. This collaboration could potentially lead to new treatment options for patients with this type of cancer.

Ligand has acquired assets of Novan, Inc. for $12.2 Million. This acquisition expands Ligand's portfolio and capabilities.

Evofem has announced that Padagis will not seek FDA approval to market a generic version of Phexxi® until Evofem's Phexxi patents expire. This announcement safeguards Evofem's market position in the interim.
Add button text ()
Facebook icon Instagram icon Twitter icon

Copyright (C) *|CURRENT_YEAR|* *|LIST:COMPANY|*. All rights reserved.
*|IFNOT:ARCHIVE_PAGE|**|LIST:DESCRIPTION|**|END:IF|*

Our mailing address is:
*|IFNOT:ARCHIVE_PAGE|**|LIST_ADDRESS|**|END:IF|*

Want to change how you receive these emails?
You can update your preferences (*|UPDATE_PROFILE|*) or unsubscribe (*|UNSUB|*)
http://eepurl.com/isHqIY